Techniques for the analyses of immunotoxin
Because a variety of disorders are treated with bone marrow transplants, the use of immunotoxins
to eliminate harmful cells prior to the procedure could have a significant impact in increasing transplant success rates and reducing hospital time.
Like the immunotoxins
, interleukin-2, a protein that stimulates the immune system's cells, causes vascular leaks at high doses.
The candidates are both immunotoxins
comprising an antibody fragment that targets the CD22 receptor on B-lymphocytes fused to a toxin molecule.
We plan to introduce this recombinant immunotoxin
into the clinic for the therapy of prostate and lung cancers.
The present Competitive Intelligence Report about Immunotoxins
provides a competitor evaluation in the field of tumor targeted toxins by means of antibodies or proteins for treatment of cancer as of July 2009.
today announced that the results of preclinical studies of its new antibody fusion protein, CD74-RNase immunotoxin
, appeared in today's issue of Blood, the official journal of the American Society of Hematology (ASH), and were also presented orally at the annual meeting of ASH on December 12, 2005, by Company Chairman, Dr.
Superior Anti-Tumor Activity of the CD19-Directed Immunotoxin
, SAR3419, to Rituximab in Non-Hodgkin's Xenograft Animal Models: Preclinical Evaluation.
9 /PRNewswire-FirstCall/ -- On November 4, 2005, Genencor, a subsidiary of Danisco A/S, divested its oncology-focused immunotoxin
program to Cambridge Antibody Technology (LONDON: CAT) .
She has been the recipient of the Pierce Immunotoxin
Award, an NIH Merit Award, 16 Faculty Teaching Awards, the FASEB Excellence in Science Award, the American Society of Microbiology Abbott Clinical Immunology Award and the American Association of Cancer Research Rosenthal Prize.
5539), entitled "A Phase I Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetic (PK) Profile of VB4-845, an anti-Ep-CAM Immunotoxin
, in Subjects with SCCHN," described updated results from a 24 patient Phase I dose-escalation trial to determine the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of intratumorally injected VB4-845.
686) entitled "A preclinical profile of Proxinium(TM), a recombinant immunotoxin
for targeting head and neck cancer," described preclinical studies that were initiated to show the specificity and safety of Proxinium(TM) and support its clinical development for the treatment of squamous cell carcinoma of the head and neck (SCCHN).